Tag - MGTX

Developments

FDA grants RPDD to MeiraGTx’s treatment for LCA1

MeiraGTx (NASDAQ:MGTX) has announced that its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1) has been granted Rare Pediatric Disease Designation (RPDD)...

January 22, 2025

Developments

MeiraGTx reports positive topline data from Phase 1/2 retinal dystrophy trial

MeiraGTx (NASDAQ:MGTX) reported that AAV-RPE65, its investigational gene therapy for the treatment of retinal dystrophy, met the primary endpoint of safety and tolerability in a Phase 1/2 study, as well as demonstrated...

May 14, 2019

Tag - MGTX

FDA grants RPDD to MeiraGTx’s treatment for LCA1

MeiraGTx reports positive topline data from Phase 1/2 retinal dystrophy trial

General

More